<DOC>
	<DOCNO>NCT00158405</DOCNO>
	<brief_summary>Interrupting HAART limit period time ( `` structure treatment interruption : STI '' ) could entail benefit ( good long term tolerance , low drug-induced viral resistance , low cost ) also concomitant risk ( low efficacy , high drug-induced viral resistance ) . At present , benefit/risk ratio STI unclear . Several STI trial progress industrialised country . This trial aim assess benefit risk two different STI strategy West Africa .</brief_summary>
	<brief_title>Randomised Trial Structured Treatment Interruption HAART HIV-Infected Adults Abidjan ( ANRS 1269 TRIVACAN )</brief_title>
	<detailed_description>The objective study assess non-inferiority two strategy structure treatment interruption ( STI ) highly active antiretroviral treatment ( HAART ) compare continuous HAART . It 's multicentric open label randomise non-inferiority trial , take place 5 health care centre Abidjan , economic capital city Cote d'Ivoire The trial design two phase : 1 . Pre-randomisation phase : 840 HAART-naive HIV-infected adult start follow continuous HAART regimen : zidovudine-lamivudine combination - preferably efavirenz , HIV-1 infect men , HIV-1 infect woman effective contraception history nevirapine-containing p-MTCT ( prevention mother child transmission ) ; - ritonavir-indinavir , HIV-2 infect patient , woman desire contraception , woman past history p-MTCT nevirapine . 2 . Trial phase : After least six month continuous HAART pre-randomisation phase , patient meet success criterion ( CD4 count 350/mm3 , undetectable viral load , absence current opportunistic infection ) randomise three arm : - Arm 1 : Continuous HAART ( 1 6 patient ) - Arm 2 : Fixed STI strategy ( 3 6 patient ) : immutable period 2 month HAART / 4 month HAART - Arm 3 : CD4-guided STI strategy ( 2 6 patient ) : unlimited interruption HAART , re-introduction/re-interruption guide evolution CD4 count . Following DSMB recommendation , arm 3 discontinue october 2005 . The trial continue patient arm 1 2 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Informed consent 18 year old CD4 count 150 350 per mm3 ( CD4 percentage 12.5 20 percent ) past history curative antiretroviral therapy residence Abidjan pregnancy severe renal failure severe hepatic failure severe neuropsychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>Structured treatment interruption</keyword>
	<keyword>HAART</keyword>
	<keyword>Sub-saharian africa</keyword>
	<keyword>Treatment Interruption</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>